<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00495287</url>
  </required_header>
  <id_info>
    <org_study_id>NILG-AML 02/06</org_study_id>
    <nct_id>NCT00495287</nct_id>
  </id_info>
  <brief_title>A Remission Induction Therapy and Risk-oriented Postremission Strategy for Adult Acute Myelogenous Leukemia (AML)</brief_title>
  <official_title>Phase III Trial in AML Comparing Standard-dose vs High-dose Remission Induction and, Within a Risk-oriented Postremission Strategy, Autologous Blood Stem Cell Transplantation vs Blood Stem Cell-supported Multicycle High-dose Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northern Italy Leukemia Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northern Italy Leukemia Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study was set up to assess:&#xD;
&#xD;
        1. Standard-dose versus high-dose remission induction therapy. A standard ICE chemotherapy&#xD;
           vs sequential high-dose cytarabine, with appropriate supportive/prophylactic measures,&#xD;
           followed by morphological, cytogenetic and molecular monitoring of remission.&#xD;
&#xD;
        2. A risk-oriented postremission therapy: HR patients will be electively submitted to&#xD;
           allogeneic stem cell transplantation (allo-SCT), whenever possible (related/unrelated&#xD;
           donor/cord blood; ablative/non-ablative conditioning according to national and local&#xD;
           protocols and guidelines). Provided sufficient blood stem cells were previously&#xD;
           collected (&gt;2x10e6/kg Cluster of Differentiation 34 cells), SR patients and HR patients&#xD;
           excluded from allo-SCT and aged 65 years or less will be randomized to: myeloablative&#xD;
           autologous blood stem cell transplantation vs non-myeloablative, multicycle, autologous&#xD;
           blood stem cell-supported high-dose cytarabine-based therapy.&#xD;
&#xD;
             -  HR/SR patients unable to be randomized because of inadequate blood stem cell yield&#xD;
                will receive intermediate-dose consolidation; patients aged &gt;65 years will be&#xD;
                treated with age-adapted therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adult AML is a difficult-to-treat illness because of both biological and therapeutic reasons.&#xD;
      Most patients are aged &gt;50 years and/or present with comorbid conditions and/or display&#xD;
      high-risk AML-related features (poor risk, cytogenetics, prior myelodysplasia, secondary&#xD;
      AML). This results in unsatisfactory response to conventional first-line therapy and makes it&#xD;
      difficult to apply the most effective post-remission consolidation options (allo-SCT in&#xD;
      younger patients with HR features, autologous blood stem cell transplantation and high-dose&#xD;
      cytarabine-based therapy in the remainder).&#xD;
&#xD;
      In a prior, phase II uncontrolled NILG trial (registered NCT 00400637),a two-step increasing&#xD;
      intensity induction was adopted in order to optimize induction results. 51% of ICE-refractory&#xD;
      cases responded to the salvage regimen, irrespective of risk class. In the same study, all HR&#xD;
      patients had to be sent to allografting whereas SR patients (by clinico-cytogenetics&#xD;
      criteria) were to receive up to three high-dose cytarabine-based cycles, each one supported&#xD;
      by a fixed amount of autologous blood-stem cells (1-2x10e6/kg Cluster of Differentiation 34&#xD;
      cells cells), to minimize the risks of high-dose cytarabine-related myelosuppression and to&#xD;
      increase treatment intensity by reducing intercycle delays. DFS was 41% at 5 years, 58% in SR&#xD;
      patients aged &lt;55 years, 47% in SR patients aged &gt;55 years, and 47% in HR patients with an&#xD;
      identifiable donor. No treatment-related death occurred during the pancytopenic phase in 118&#xD;
      patients receiving 299 blood stem-cell supported high-dose cytarabine cycles.&#xD;
&#xD;
      These facts led to the present trial, in which 1) high-dose induction formerly used as&#xD;
      salvage is directly compared to standard ICE chemotherapy and 2) the blood-stem cell&#xD;
      supported multicycle high-dose cytarabine program is directly compared to a standard&#xD;
      autologous blood stem cell transplantation.&#xD;
&#xD;
      RANDOM 1 CYCLE 1&#xD;
&#xD;
        -  Standard ICE (all drugs by IV route): idarubicin 12 mg/m2/d on dd 1-3, cytarabine 100&#xD;
           mg/m2/bd on dd 1-7, etoposide 100 mg/m2/d on dd 1-5, G-CSF from d 11.&#xD;
&#xD;
        -  High-dose sequential (all drugs by IV route): cytarabine 2* g/m2/bd on dd 1-2 and 8-9,&#xD;
           idarubicin 18 mg/m2/d on dd 3 and 10, G-Colony Stimulating Factory (G-CSF) from d 11. *1&#xD;
           g/m2 in frail patients aged 60-65 and in all those aged &gt;65 years.&#xD;
&#xD;
      CYCLE 2 (if CR achieved after cycle 1): Standard IC: idarubicin 10 mg/m2/d on dd 1-3,&#xD;
      cytarabine 100 mg/m2/bd on dd 1-7, G-CSF.&#xD;
&#xD;
      CYCLE 3: Intermediate-dose cytarabine 1 g/m2/bd on dd 1-4 followed by G-CSF and by stem cell&#xD;
      collection (1-2x10e6/kg CD34+ cells in three separate bags)&#xD;
&#xD;
      ALLO-SCT (Allogeneic Stem Cells Transplantation): All HR patients are eligible to allo-SCT as&#xD;
      first therapeutic option. Allo-SCT procedure: any type according to local&#xD;
      protocols/guidelines.&#xD;
&#xD;
      RANDOM 2&#xD;
&#xD;
      All SR patients and HR ones excluded from allo-SCT:&#xD;
&#xD;
        -  Autologous blood stem cell transplantation after BU-CY2 regimen (Busulfan 0.8 mg/kg IV&#xD;
           on dd -8 to -5, Cy 60 mg/kg/d on dd -4 to -3, autograft on d 0 (2-6x10e6/kg CD34+ cells)&#xD;
           and G-CSF from d +1.&#xD;
&#xD;
        -  Autologous blood stem cell supported multicycle therapy (x3, monthly) with cytarabine 2&#xD;
           g/m2/bd on dd 1-5, idarubicin 8 mg/m2/d on dd 1-2, autograft on d 6 (1-2x10e6/kg CD34+&#xD;
           cells) and G-CSF from d 8.&#xD;
&#xD;
      Patients excluded from Random 2 as well as from allo-SCT receive attenuated, unsupported&#xD;
      consolidation with 1-2 intermediate-dose cytarabine cycles. Patients aged &gt;65 years are&#xD;
      excluded from Random 2.&#xD;
&#xD;
      RISK CLASSIFICATION Cytogenetic risk classification is based on MRC/ECOG-SWOG/CALGB criteria&#xD;
      (cytogenetic risk classes: favorable, normal/intermediate, unfavorable, other, unknown);&#xD;
      clinical risk classification is based on selected diagnostic criteria and response to&#xD;
      chemotherapy cycle 1. The final risk model integrates cytogenetic and clinical risk to&#xD;
      encompass two broad risk classes (SR and HR).&#xD;
&#xD;
        -  Standard risk (SR): favorable cytogenetics, CR achieved after cycle 1; or&#xD;
           normal/intermediate cytogenetics, CR achieved after cycle 1, lack of high-risk&#xD;
           characteristics.&#xD;
&#xD;
        -  High risk (HR): unfavorable cytogenetics; or normal/intermediate cytogenetics with any&#xD;
           high-risk characteristic (WBC &gt;50x10e9/l,FAB M0,6,7 or corresponding WHO, secondary AML,&#xD;
           Myelodysplastic Syndrome (MDS)-associated AML, hepatosplenomegaly, FLT3 mutation, CR)&#xD;
           not achieved with cycle, persistent cytogenetic abnormality at CR), or other/unknown&#xD;
           cytogenetics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission induction (R1): Complete remission (CR) rate after cycle 1</measure>
    <time_frame>30 days after beginning chemotherapy.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Remission consolidation (R2): Length of remission (DFS, disease-free survival)</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>R1: CR with incomplete hematological recovery</measure>
    <time_frame>30 days after beginning chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R1:Complete cytogenetic remission</measure>
    <time_frame>30 days after beginning chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R1: Treatment-related death (TRD)</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R2: Overall survival (OS)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission duration and cumulative incidence of relapse</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related death</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>1 year and 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">573</enrollment>
  <condition>Acute Myelogenous Leukemia</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remission induction arm A is with conventional chemotherapy cycle (&quot;ICE&quot;: idarubicin, standard-dose cytarabine, etoposide)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Remission induction therapy with high-dose cytarabine sequential regimen (HD-Ara-C, idarubicin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytosine arabinoside</intervention_name>
    <description>Arm A: use of standard-dose cytosine arabinoside (100 mg/m2/bd iv. on days 1-7) in association with idarubicin and etoposide.&#xD;
Arm B: use of high-dose cytosine arabinoside (1000-2000 mg/m2/bd according to age +/-65 years iv. on days 1-2 and 8-9) in association with idarubicin.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Aracytin</other_name>
    <other_name>Cytarabine</other_name>
    <other_name>Cytosar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria (Random 1):&#xD;
&#xD;
          -  Age 16+ years&#xD;
&#xD;
          -  Diagnosis of untreated (or only hydroxyurea/cyclophosphamide) acute myelogenous&#xD;
             leukemia (AML, including myeloid sarcoma) or high-risk myelodysplasia (RAEB-2), either&#xD;
             de novo or following an antecedent hematological disorder, or secondary to&#xD;
             chemo-radiotherapy for other cancer&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Adequate sampling for full cytological, cytochemical, cytogenetic and immunobiological&#xD;
             disease characterization by revised FAB, EGIL and WHO criteria&#xD;
&#xD;
          -  ECOG performance status 0-2 or reversible ECOG 3 score following intensive care of&#xD;
             complications.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Diagnosis of acute promyelocytic leukemia&#xD;
&#xD;
          -  Pre-existing, uncontrolled pathology such as cardiac disease (congestive/ischemic,&#xD;
             acute myocardial infarction within the past 3 months, untreatable arrythmias, NYHA&#xD;
             classes III and IV), severe liver disease with serum bilirubin &gt;3 mg/dL and/or ALT &gt;3&#xD;
             x upper normal limit (unless attributable to AML), kidney function impairment with&#xD;
             serum creatinine &gt;2 mg/dL (unless attributable to AML), and severe neuropsychiatric&#xD;
             disorder that impairs the patient's ability to understand and sign the informed&#xD;
             consent, or to cope with the intended treatment plan&#xD;
&#xD;
          -  Known HIV positive serology&#xD;
&#xD;
          -  Other active hematological or non-hematological cancers with life expectancy &lt;1 year&#xD;
&#xD;
          -  Pregnancy (fertile women will be advised not to become pregnant while on treatment;&#xD;
             and male patients to adopt contraceptive methods)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renato Bassan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Norther Italy Leukemia Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dipartimento di Ematologia e Medicina Trasfusionale - Azienda Osp. Nazionale Santi Antonio e Biagio e Cesare Arrigo</name>
      <address>
        <city>Alessandria</city>
        <state>AL</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC Ematologia Azienda Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <state>BG</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Generale di Bolzano</name>
      <address>
        <city>Bolzano</city>
        <state>Bz</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. Ematologia - Azienda Ospedaliera S.Croce e Carle</name>
      <address>
        <city>Cuneo</city>
        <state>CN</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia - AOU Careggi</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia Centro TMO - Fondazione IRCSS Ospedale Maggiore</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia e TMO - Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Dei Tumori</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia - TMO - Ospedale San Gerardo</name>
      <address>
        <city>Monza</city>
        <state>MI</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U San Giovanni Battista-Divisione Ematologica dell'Università</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia 2 - Osp. Molinette San Giovanni Battista</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Mauriziano</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale dell'Angelo</name>
      <address>
        <city>Mestre</city>
        <state>Venezia</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituti Ospitalieri</name>
      <address>
        <city>Cremona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Circolo di Varese</name>
      <address>
        <city>Varese</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>July 2, 2007</study_first_submitted>
  <study_first_submitted_qc>July 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2007</study_first_posted>
  <last_update_submitted>March 29, 2016</last_update_submitted>
  <last_update_submitted_qc>March 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northern Italy Leukemia Group</investigator_affiliation>
    <investigator_full_name>DR RENATO BASSAN</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>Acute myelogenous leukemia</keyword>
  <keyword>Adult patients</keyword>
  <keyword>Cytogenetic risk class</keyword>
  <keyword>Clinico-cytogenetic risk model</keyword>
  <keyword>Risk-oriented therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

